Mark Clemons

List of Publications by Year in Descending Order

26 papers	3,660 citations	17 h-index	27 g-index
27 ext. papers	4,101 ext. citations	10 avg, IF	4.78 L-index

#	Paper	IF	Citations
26	Developing patient-centred strategies to optimize the management of vasomotor symptoms in breast cancer patients: a survey of health care providers. *Breast Cancer Research and Treatment*, **2021**, 188, 343-350	4.4	2
25	Creating a pragmatic trials program for breast cancer patients: Rethinking Clinical Trials (REaCT). *Breast Cancer Research and Treatment*, **2019**, 177, 93-101	4.4	10
24	Randomised feasibility trial to compare three standard of care chemotherapy regimens for early stage triple-negative breast cancer (REaCT-TNBC trial). *PLoS ONE*, **2018**, 13, e0199297	3.7	2
23	Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. *European Journal of Cancer*, **2018**, 103, 147-154	7.5	38
22	Enhancing accrual to chemotherapy trials for patients with early stage triple-negative breast cancer: a survey of physicians and patients. *Supportive Care in Cancer*, **2017**, 25, 1881-1886	3.9	8
21	Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncology, The*, **2017**, 18, 904-916	21.7	330
20	PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer. *Cell Metabolism*, **2015**, 22, 577-89	24.6	308
19	Platinum-based chemotherapy in triple-negative advanced breast cancer. *Breast Cancer Research and Treatment*, **2014**, 146, 567-72	4.4	26
18	Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression. *Oncology Letters*, **2014**, 7, 866-870	2.6	7
17	Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. *Breast Cancer Research*, **2013**, 15, R88	8.3	139
16	Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. *Cancer Treatment Reviews*, **2012**, 38, 708-14	14.4	128
15	Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes. *Molecular and Cellular Biology*, **2012**, 32, 2979-91	4.8	72
14	Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. *Lancet Oncology, The*, **2011**, 12, 852-61	21.7	883
13	Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. *Clinical Breast Cancer*, **2009**, 9, 29-33	3	303
12	Should a biopsy be recommended to confirm metastatic disease in women with breast cancer?. *Lancet Oncology, The*, **2009**, 10, 933-5	21.7	31
11	A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. *Supportive Care in Cancer*, **2008**, 16, 577-83	3.9	151
10	Identifying menopause in breast cancer patients: considerations and implications. *Breast Cancer Research and Treatment*, **2007**, 104, 115-20	4.4	27

List of Publications

9	Survival differences observed in metastatic breast cancer patients treated with capecitabine when compared with vinorelbine after pretreatment with anthracycline and taxane. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2007**, 30, 297-302	2.7	19
8	Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer. *Oncologist*, **2006**, 11, 227-33	5.7	27
7	Can bone markers guide more effective treatment of bone metastases from breast cancer?. *Breast Cancer Research and Treatment*, **2006**, 97, 81-90	4.4	15
6	Should oral bisphosphonates be standard of care in women with early breast cancer?. *Breast Cancer Research and Treatment*, **2005**, 90, 315-8	4.4	5
5	Perspectives on the future of bisphosphonate use in breast cancer patients. *Seminars in Oncology*, **2004**, 31, 87-91	5.5	9
4	Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. *Journal of Clinical Oncology*, **2003**, 21, 4175-83	2.2	292
3	Hormonal risk factors for breast cancer: identification, chemoprevention, and other intervention strategies. *Lancet Oncology, The*, **2002**, 3, 611-9	21.7	32
2	Management of the menopause in cancer survivors. *Cancer Treatment Reviews*, **2002**, 28, 321-33	14.4	7
1	Estrogen and the risk of breast cancer. *New England Journal of Medicine*, **2001**, 344, 276-85	59.2	789